We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

13 hedge funds and large institutions have $47.9M invested in NKGen Biotech, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

27% less capital invested

Capital invested by funds: $65.3M → $47.9M (-$17.4M)

48% less funds holding

Funds holding: 25 → 13 (-12)

92% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 13

Holders
13
Holders Change
-12
Holders Change %
-48%
% of All Funds
0.21%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
1
Increased
3
Reduced
3
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MC
Meteora Capital
Florida
+$21M
2
DC
Diametric Capital
Massachusetts
+$4.79M
3
RCM
Rivernorth Capital Management
Florida
+$756K
4
CS
Clear Street
New York
+$745K

Top Sellers

Rank Fund Capital Flow
1
RCM
Radcliffe Capital Management
Pennsylvania
-$6.63M
2
MF
Magnetar Financial
Illinois
-$6.41M
3
FTCM
Fir Tree Capital Management
New York
-$5.68M
4
UOC
UBS O'Connor
Illinois
-$3.27M
5
KL
KIM LLC
Kansas
-$3.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
SSA
26
Schonfeld Strategic Advisors
New York
– -$115K -11,085 Closed
1
2

NKGN Hedge Fund Activity: Q3 2023 in Review

13 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q3 2023, worth a combined $47.9M — down 27% from $65.3M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of NKGN and 1 opened new positions — a net loss of 12 holders — while 3 trimmed existing stakes and 3 added.

The largest buyer was Meteora Capital, adding an estimated $21M. The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $6.63M sold.

  • 13 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q3 2023, down from 25 in Q2 2023.
  • Funds reported $47.9M of NKGen Biotech, Inc. Common Stock stock for Q3 2023, down 27% quarter-over-quarter.
  • 1 fund opened new NKGen Biotech, Inc. Common Stock positions in Q3 2023 and 13 closed out, a net change of -12 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q3 2023 was Meteora Capital, an estimated $21M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q3 2023 was Radcliffe Capital Management, an estimated $6.63M sold.

Based on aggregated 13F filings for Q3 2023.